Patent · US Active

Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals

US8551977B2 · kind B2 · utility

0Cited by

8References

19Claims

0Family size

Assignee

Aeterna Zentaris, Inc. · DE

Inventors

Jurgen Engel · Alzenau, DE
Eckhard Gunther · Offenbach, DE
Herbert Sindermann · Rodgau, DE

Key dates

Filing date	Mar 31, 2010
Grant date	Oct 8, 2013
Priority date	—
Expiry date	Oct 2, 2030

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the use of alkylphosphocholines in combination with antimetabolite antitumor substances for the treatment of benign and malignant oncoses in humans and animals. It is possible in this connection for the alkylphosphocholines to be employed in a combination according to the invention with one or more antimetabolite antitumor substances. Preferred alkylphosphocholines are described by the Formula II.One such preferred alkylphosphocholine is perifosine.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.